Role of Immunotherapy for Renal Cell Cancer in 2011

George, Saby; Пили, Роберто; Carducci, Michael A.; Kim, Jaeyeon

doi:10.6004/jnccn.2011.0085

Cited by 23 publications

(19 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, despite the use of a single-agent interferon, which has decreased significantly since the introduction of targeted therapy, it remains in the frontline setting in combination with bevacizumab as a result of 2 large phase III trials [24,25]. Lastly, improved understanding of immune regulation has led to the advancement of targeted immunotherapy using immune checkpoint inhibitors that have shown promising activity and that are moving forward in clinical development [26]. …”

Section: Immunotherapy For Mrccmentioning

confidence: 99%

Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma

Cho

Chung

2012

Korean J Urol

View full text Add to dashboard Cite

The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being predominantly cytokine-based treatment to the use of targeted agents, which include sorafenib, sunitinib, bevacizumab (plus interferon alpha [IFN-α]), temsirolimus, everolimus, pazopanib, and most recently, axitinib. Improved understanding of the molecular pathways implicated in the pathogenesis of RCC has led to the development of specific targeted therapies for treating the disease. In Korea, it has been 5 years since targeted therapy became available for mRCC. Thus, we now have broader and better therapeutic options at hand, leading to a significantly improved prognosis for patients with mRCC. However, the treatment of mRCC remains a challenge and a major health problem. Many questions remain on the efficacy of combination treatments and on the best methods for achieving complete remission. Additional studies are needed to optimize the use of these agents by identifying those patients who would most benefit and by elucidating the best means of delivering these agents, either in combination or as sequential single agents. Furthermore, numerous ongoing research activities aim at improving the benefits of the new compounds in the metastatic situation or their application in the early phase of the disease. This review introduces what is currently known regarding the fundamental biology that underlies clear cell RCC, summarizes the clinical evidence supporting the benefits of targeted agents in mRCC treatment, discusses survival endpoints used in pivotal clinical trials, and outlines future research directions.

show abstract

Section: Immunotherapy For Mrccmentioning

confidence: 99%

Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma

Cho

Chung

2012

Korean J Urol

View full text Add to dashboard Cite

show abstract

“…The dosing schedule for HD IL-2 therapy was defined as intravenous infusion every 8 hours over 15 minutes on days 1 through 5 and days 15 through 19, with a maximum of 12 to 15 doses per admission and 2 admissions constituting a single treatment cycle [5,8]. Up to 3 treatment cycles, each separated by 6 to 8 weeks, are usually recommended for patients who demonstrate a response and tolerate treatment [14]. Although definitions of treatment cycle may vary across institutions, failure to receive more than 1 cycle as defined earlier suggests lack of response, progression, or toxicity.…”

Section: Methodsmentioning

confidence: 99%

Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States

Allard

Gelpi-Hammerschmidt

Harshman

et al. 2015

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Background Targeted therapies (TTs) have revolutionized metastatic renal cell carcinoma (mRCC) treatment in the past decade, largely replacing immunotherapy including high-dose interleukin-2 (HD IL-2) therapy. We evaluated trends in HD IL-2 use for mRCC in the TT era. Methods Our cohort comprised a weighted estimate of all patients undergoing HD IL-2 treatment for mRCC from 2004 to 2012 using the Premier Hospital Database. We assessed temporal trends in HD IL-2 use including patient, disease, and hospital characteristics stratified by era (pre-TT uptake: 2004–2006, uptake: 2007–2009, and post-TT uptake: 2010–2012) and fitted multivariable regression models to identify predictors of treatment toxicity and tolerability. Results An estimated 2,351 patients received HD IL-2 therapy for mRCC in the United States from 2004 to 2012. The use decreased from 2004 to 2008. HD IL-2 therapy became increasingly centralized in teaching hospitals (24% of treatments in 2004 and 89.5% in 2012). Most patients who received HD IL-2 therapy were men, white, younger than 60 years, had lung metastases, and were otherwise healthy. Vasopressors, intensive care unit admission, and hemodialysis were necessary in 53.4%, 33.0%, and 7.1%, respectively. Factors associated with toxicities in multivariable analyses included being unmarried, male sex, and multiple metastatic sites. African Americans and patients with single-site metastases were less likely to receive multiple treatment cycles. Conclusions HD IL-2 therapy is used infrequently for mRCC in the United States, and its application has diminished with the uptake of TT. Patients are being increasingly treated in teaching hospitals, suggesting a centralization of care and possible barriers to access. A recent slight increase in HD IL-2 therapy use likely reflects recognition of the inability of TT to effect a complete response.

show abstract

“…We should therefore assess the immune status of post-operative patients with renal cancer. Current standards of care include the administration of bio-therapy and certain immunoregulatory drugs to maintain higher levels of immune status to prevent or delay the recurrence of tumors (George et al, 2011;Mesiano et al, 2012). Therefore, we treated patients post-operatively with DC-CIK bio-therapy and IFN-α therapy.…”

Section: Discussionmentioning

confidence: 99%

“…All patients had received nephrectomy combined with dendritic cell and cytokine-induced killer cell (DC-CIK) therapy (Mesiano et al, 2012) or interferon-α (IFN-α) therapy (George et al, 2011). Postoperative pathologic results showed there were 83 patients with suprarenal epithelioma, 7 with papillary cellular carcinoma, 8 with chromophobic cellular tumor, and 3 with other cellular tumors.…”

Section: Subjectsmentioning

confidence: 99%

Lack of clinical significance of the ImmuKnowTM-Cylex assay for the detection of cellular immune function in patients with renal cell carcinoma

et al. 2015

View full text Add to dashboard Cite

ABSTRACT. This study aimed to explore the clinical value of the CD4 + T cell ATP levels in patients with renal cell carcinoma through the application of the ImmuKnow TM -Cylex ® assay. We recruited 104 patients with renal cancer who had undergone surgery at Fuzhou General Hospital from March 2009 to June 2012, and were subsequently treated by dendritic cell and cytokine-induced killer cell bio-therapy or interferon-α therapy. The changes in CD4 + T cell ATP levels were detected at the perioperative period and at 10 days, 1 month, 3 months, and 1 year after the surgery using the ImmuKnow assay. In addition, the differences in ATP levels in different therapy groups were compared and the prognosis conditions were analyzed. Our results demonstrated that no significant difference in the ATP levels occurred at different time points; furthermore, there were no obviously different ATP levels between the different therapy groups, and the ATP levels were found K. Zheng et al.

show abstract

Role of Immunotherapy for Renal Cell Cancer in 2011

Cited by 23 publications

References 51 publications

Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma

Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma

Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States

Lack of clinical significance of the ImmuKnowTM-Cylex assay for the detection of cellular immune function in patients with renal cell carcinoma

Contact Info

Product

Resources

About